Orlando, Fla.—A registry has documented relatively high rates of long-term survival among patients with secondary acute myeloid leukemia (sAML) who undergo hematopoietic cell transplantation (HCT).
Two-year overall survival (OS) in this registry—the largest cohort of patients receiving HCT for sAML—is 46%, and 31% of patients remained leukemia-free five years after transplant.
The registry study, initiated in the year 2000, has generated a variety of potentially useful